Valeritas Holdings Inc

Valeritas — Investor Presentation (October 2018)

31 slides from Valeritas's investor presentation, Oct 12, 2018

  1. Slide 1: Valeritas Corporate Presentation

    Valeritas Corporate Presentation NASDAQ: VLRX October 2018 Improving health and simplifying life for people with diabetes ©2018 Valeritas, Inc.

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to purchase securities. Any sale by the company shall be made pursuant to a definitive purchase agreement. Unless otherwise stated in this presentation, references to “Valerita

  3. Slide 3: Rapidly Ramping Revenue & Poised for Significant Value Creation

    Valeritas: Rapidly Ramping Revenue & Poised for Significant Value Creation Consistent Robust Highly Attractive Unrivaled Market Top-Line Growth Financial Profile Opportunity  30%+ YoY growth and  Gross Margins ~50%  Global Type 2 diabetes accelerating tracking to 80% pandemic  New commercial mod

  4. Slide 4: Accelerating Revenue Growth in a Massive Market

    Accelerating Revenue Growth in a Massive Market Establishing a high-touch & higher-service sales model has been the key to unlocking Valeritas’ growth $7,000 Sequential Quarterly Revenue (Q2 2016 - Q2 2018) $6,500 $6,000 Began initiating components of new model with $5,500 fewer reps (in 000’s) (in

  5. Slide 5: New Higher-Service Sales and Marketing Model

    New Higher-Service Sales and Marketing Model Model validated, driving targeted account penetration and robust top-line growth DIRECT SALES REPs ON-LINE ADs INDIRECT REPs EDUCATION PROMOTION DEMO KIT EDUCATORs DESIRE PRESCRIBE TARGETED KOLs PRINT ADs PATIENT PHYSICIAN DIRECT-TO- • Activate patients t

  6. Slide 6: New Sales Model Validation – Key Metrics

    New Sales Model Validation – Key Metrics Key sales metrics validate our Med Tech sales model drives a highly effective, efficient and scalable commercial organization capable of meaningful market penetration “Old” Pharma Sales “New” Med Tech Sales Model Model Q2 ’18 CFBE (2022E) # of 75 50 75 Sales

  7. Slide 7: Direct Sales Footprint – Significant Organic Growth Opportunity

    Direct Sales Footprint – Significant Organic Growth Opportunity With sales model validated top-line growth can be accelerated by disciplined sales force expansion . Currently ~50 direct reps . Add ~25 direct reps & additional CDEs over time . Large markets under- represented or uncovered . Potential

  8. Slide 8: Valeritas' Massive U.S. Market Opportunity – Our Core Focus

    Valeritas’ Massive U.S. Market Opportunity – Our Core Focus 15% share penetration generates ~$1.6B U.S. Opportunity U.S. Diabetes Market1 Valeritas’ Target Market – Type 2 on Insulin ~23M diagnosed with diabetes 5.6M on Insulin (90%-95% Type 2)2 80% Not Achieving A1c Goal3,4 Type 2 Type 2 Not on Ins

  9. Slide 9: Diabetes A Global Pandemic

    Diabetes A Global Pandemic - ~380M Type 2 Patients Partnering with experienced high quality regional diabetes distributors Global Diabetes Stats1 International Distribution Agreements . Currently 425 million suffer diabetes; expected to be . Recent international distribution 629 million by 2045 (~90

  10. Slide 10: Key Problem Managing Type 2 Diabetes

    Key Problem Managing Type 2 Diabetes “Drugs don’t work in people who don’t take them” – C. Everett Koop, M.D.1 Type 2 Insulin Users Intentionally Skip and/or Current Insulin Delivery Standard of Care Forget to Take Injections2 Most Type 2 patients will not inject away from home3 1. Eur J Heart Fail.

  11. Slide 11: Our Solution, V-Go: Discreet, Effective & Simple to Use

    Our Solution, V-Go®: Discreet, Effective & Simple to Use Designed for the Type 2 Patient V-Go’s Benefits Discreet Simple to Use Convenient Better A1c Control* Cost Neutral Self-contained Sharps Container Pharmacy vs. DME * Company data, kff.org (13 published clinical papers and 58 presentations at N

  12. Slide 12: V-Go Competition: Pens not Pumps

    V-Go® Competition: Pens not Pumps Unique Needs of Type 2 Patients Creates Valeritas’ Opportunity & Differentiates it from Others TYPE 1 TYPE 2 Typical Patient Engaged / Advocate Embarrassment / Stigma Attitude Complex Device More Likely Less Likely Acceptable? (~30% of Type 1 are on pump therapy)1 W

  13. Slide 13: Strong Clinical Evidence

    Strong Clinical Evidence Demonstrated Statistically Significant Improvements in A1c1-11 Published 13 Clinical Papers Improved Diabetes Management Performance Measures4,7,9,10,11 V-Go Patients >1,500 Studied Lowered Total Daily Dose of Insulin Presentations 1-11 (Prescribed / Administered) at Nationa

  14. Slide 14: V-Go: Improved A1c Control with Less Insulin

    V-Go®: Improved A1c Control with Less Insulin A Prospective Study of 415 Patients Showed V-Go Superiority vs. Standard Treatment Optimization (STO)1 Greater Improvement in A1c2 Less Insulin Used & More Cost Effective V-Go STO n=169 n=246 29% Less Insulin with V-Go vs STO at 4 months (54 vs 72 u/day)

  15. Slide 15: Robust Pipeline to Drive Long-Term Growth

    Robust Pipeline to Drive Long-Term Growth V-Go® is a platform with the potential to disrupt the diabetes & insulin markets V-Go® SIMTM V-Go® Prefill1,3 h-PatchTM4 (Simple Insulin Management)1,2 Being developed to: (core technology behind V-Go) Being developed to: • Eliminate filling step as it would

  16. Slide 16: Growth and Milestones to Drive Significant Shareholder Value

    Growth and Milestones to Drive Significant Shareholder Value Grow Our Share Expand Our Reach Leverage Pipeline Launch Expand V-Go Prefill Advance Sales Force Product Launch V-Go Next in U.S. Collaborate V-Go SIMTM Gen / Line Launch with (Int’l) Extensions Payors V-Go SIMTM Expand h-Patch Expansion o

  17. Slide 17: Strong Gross Margin Mitigates Capital Needs to Break-Even

    Strong Gross Margin Mitigates Capital Needs to Break-Even Planned capital raise expected to fund through break-even Quarterly Revenue Level at Which 45% Historical and Projected Gross Margin Gross Margin was Achieved* vs. ($ in million) Revenue $61.1 ~30% 80% Margin Improvement $26-28M $20M $20M 50%

  18. Slide 18: Components Of Expected Gross Margin Improvement

    Components Of Expected Gross Margin Improvement V-Go’s design and low-cost production empowers a best-in-class gross margin profile that significantly reduces future cash need to break-even 2022E @ 2018E Key Drivers Of Gross Margin Improvement Comments CFBE •1 Expected growth significantly ~80.0% re

  19. Slide 19: Financial Summary

    Financial Summary Financial Summary Quarterly Summary YTD Summary ($ in millions) 2Q18 2Q17 Change 2018 2017 Change Revenue $6.5 $4.8 +36% $12.6 $9.4 +34% Gross Profit $3.1 $1.8 +71.5% $6.0 $3.5 +69.4% Gross Margin 47.6% 37.7% +990 bp 47.6% 37.6% +1000 bp Net Loss $11.0 $12.0 -7.5% $22.7 $23.8 -4.6%

  20. Slide 20: Rapidly Ramping Revenue & Poised for Significant Value Creation

    Valeritas: Rapidly Ramping Revenue & Poised for Significant Value Creation Consistent Robust Highly Attractive Unrivaled Market Top-Line Growth Financial Profile Opportunity  30%+ YoY growth and  Gross Margins ~50%  Global Type 2 diabetes accelerating tracking to 80% pandemic  New commercial mod

  21. Slide 21: Appendix

    Valeritas Corporate Presentation Appendix NASDAQ: VLRX October 2018 ©2018 Valeritas, Inc.. 21

  22. Slide 22: 4.5M U.S. Type 2 Patients on Insulin are not Achieving A1c Goal

    4.5M U.S. Type 2 Patients on Insulin are not Achieving A1c Goal Despite Serious Health Consequences % of Type 2 Patients on Insulin NOT at Goal1 Impact of Improving A1c Control2 Every 1% improvement in A1c decreases diabetes related events in: AT A1c Goal NOT AT A1c Goal 20% 80% Deaths Heart Attacks

  23. Slide 23: Significant Market Opportunity for Valeritas in the U.S.

    Significant Market Opportunity for Valeritas in the U.S. U.S. Type 2 Diabetes Initial V-Go® Target Market V-Go Potential Revenue 5.6M Patients with Type 2 2M Type 2 on Multiple Daily Injections Diabetes On Insulin1 With Current Sales Force 15% “IF” Market Share V-Go Revenue 2 2M on 15% $75 Million M

  24. Slide 24: Robust Clinical Data Validated Ability of V-Go

    Robust Clinical Data Validated Ability of V-Go® to Deliver Clinically Relevant Reductions in A1c with Less Insulin V-GoAL1 SIMPLE2 VALIDATE 13 EVIDENT4 IMPROVE5 JONES6 KAISER7 UMASS8 MOTIV9 ENABLE10 Baseline 9.9% 8.8% 9.6% 9.6% 9.8% 9.1% 9.8% 10.7% 8.7% 9.2% N=169 N=87 N=204 N=85 N= 103 N=69 N=60 N=

  25. Slide 25: Simple Titration Approach Significantly Lowered A1c

    Simple Titration Approach Significantly Lowered A1c Use of a weekly physician-driven mealtime dosing titration approach with patients with Type 2 Diabetes uncontrolled on prior regimens A1c (%) Insulin Dose (Units) A1c Goal Achievement 8.7 144 Before V-Go® On V-Go < 7% 13% 47% < 8% 40% 7.1* 87% 60*

  26. Slide 26: Less Insulin Needed and Lower A1c vs. Multiple Injections

    Less Insulin Needed and Lower A1c vs. Multiple Injections Switching from Prior Multiple Daily Injections to V-Go® Results in Significant Reductions in Insulin and A1c VALIDATE evaluated patients switched to V-Go when Glycemic Control was Suboptimal on Prior Regimens Prescribed On V-Go 117 Patient 10

  27. Slide 27: Clinical Benefit Realized with V-Go

    Clinical Benefit Realized with V-Go® Switching Patients from Prior Insulin Injections to V-Go Resulted in Improved A1c and Less Insulin Regardless of Baseline Insulin Regimen or Dose All Patients Switched to V-Go1 Patients with High Dose MDI Switched to V-Go2 (MDI Patients Prescribed between 90- 300

  28. Slide 28: Patients Who Utilize V-Go Like How it Fits into Their Lifestyle

    Patients Who Utilize V-Go® Like How it Fits into Their Lifestyle >90% of Patients are satisfied with the ability of V-Go to fit with their Lifestyle Extremely Satisfied = 39% Very Satisfied= 32% Satisfied= 16% Somewhat Satisfied= 7% Not Satisfied=6% N=720 patients prescribed V-Go dLife Survey 1Q 201

  29. Slide 29: V-Go with V-Go SIM Technology

    V-Go® with V-Go SIMTM Technology Simple Insulin Management™ MANAGEMENT APPLICATIONS PATIENT PHYSICIAN INDUSTRY PAYERS V-Go SIM sends data one-way to a V-Go SIM will enable simple and Adherence, utilization and other Evidence of treatment smart device. SIM App provides data timely access to data that

  30. Slide 30: Easy to Use & High Quality Commercial Scale Manufacturing

    V-Go®: Easy to Use & High Quality Commercial Scale Manufacturing V-Go Device Overview V-Go® EZ FILL Basal rate is 24 hour Basal rate begins spring-driven with the push of a button Basal rate flow restrictor Needle • Simple filling does not require calculations, measuring On-demand bolus or needles f

  31. Slide 31: Experienced and Proven Executive Management Team

    Experienced and Proven Executive Management Team Geoffrey Jenkins EVP Manufacturing Joseph Saldanha Operations, R&D Chief Business Officer John Timberlake President & CEO, Board Member Matt Nguyen ErickLucera Chief Commercial Officer Chief Financial Officer ©2018 Valeritas, Inc. 31

Valeritas Holdings — Investor Presentation (October 2018) on 6ix